Was the GlaxoSmithKline FCPA resolution a missed opportunity?
Tom Fox questions whether U.S. regulators missed a chance to illustrate how they would give credit for anti-corruption prosecutions done by other governments in the case of GlaxoSmithKline’s China subsidiary’s recent FCPA resolution.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
OpinionTime to end 'desktop compliance' in public procurement in Latin America
Global corporate compliance has reached an inflection point. For years, multinational corporations have based their Third-Party Risk Management programs in Latin America on standardized questionnaires and certificates issued by local governments.
-
ArticleGavin Proudley, SVP Risk & Compliance at Dow Jones, on compliance challenges from divergent rules and geopolitics
Diverging global rules, sanctions, and tariffs being “weaponized,” and more have made compliance complex even before the U.S. strikes on Iran. We asked Gavin Proudley, SVP Risk & Compliance at Dow Jones, what this means for compliance managers and how they can stay ahead of shifting geopolitics and tighter ...
-
ArticleEx-Capula CCO refiles whistleblower retaliation lawsuit
The former U.S. chief compliance officer of London-based hedge fund Capula Investment Management, who alleged he was fired for escalating “significant regulatory compliance issues” to senior management, refiled his lawsuit in state court after his original complaint was dismissed in federal court on jurisdictional grounds.